Naval Daver

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0001-7103-373X

发表论文 1545 篇 · 总被引 35535 次 · h-index 91

代表论文

• Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia (2026 · Cancer)
• Microclone with megaimpact (2026 · Blood)
• Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study (2026 · Journal of Clinical Oncology)
• Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm (2026 · Blood)
• Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model (2026 · Journal of Clinical Oncology)
• Table S18 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial (2026)